<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875664</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024327</org_study_id>
    <nct_id>NCT03875664</nct_id>
  </id_info>
  <brief_title>Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy</brief_title>
  <official_title>Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this randomized double-blind clinical trial is to evaluate the effect of
      intraoperative infiltration of liposomal bupivacaine at the time of posterior colporrhaphy
      and/or perineorrhaphy on postsurgical pain scores during the first 72 hours after surgery as
      measured by visual analog scales (VAS) for patients undergoing surgery for pelvic organ
      prolapse. Study subjects are randomized to 30 mL of liposomal bupivacaine versus 30 mL of
      injectable normal saline administered in a standardized technique into the posterior vaginal
      compartment at the time of posterior repair and/or perineorrhaphy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liposomal bupivacaine (EXPAREL; Pacira Pharmaceuticals, San Diego, CA) is an extended release
      local anesthetic approved by the Food and Drug Administration since 2011 for the treatment of
      postsurgical pain. It is a multivesicular liposomal delivery system, consisting of a liquid
      bupivacaine core encapsulated by a phospholipid shell. This delivery technology allows for
      the slow, sustained release of bupivacaine over at least 72 hours.

      Liposomal bupivacaine has been studied extensively in the general surgery and orthopedic
      surgery literature. Specifically, infiltration of liposomal bupivacaine after excisional
      hemorrhoidectomy has been shown to significantly lower postsurgical pain scores, decrease
      total postoperative opioid requirements, increase the number of patients who do not require
      any opioids after surgery, meaningfully delay the median time to first opioid use, and
      improve patient satisfaction with overall perioperative analgesia.

      Posterior colporrhaphy and perineorrhaphy are pelvic reconstructive surgical procedures that
      are associated with significant postsurgical localized pain resulting from surgical
      incisions. Investigators hypothesize this localized postsurgical pain will benefit from
      treatment with an extended release local anesthetic formulation similar to hemorrhoidectomy.
      Intraoperative infiltration of a standard local anesthetic during posterior repair and
      perineorrhaphy has been shown to improve early analgesia and facilitate early postoperative
      recovery. These findings reiterate the need for studies investigating a slow-release,
      longer-acting local anesthetic formulation for patients undergoing posterior repair and/or
      perineorrhaphy - one that ideally can be integrated into an evidence-based, opioid-sparing
      postsurgical pain management regimen to improve perioperative care for the steadily growing
      pelvic reconstructive surgical patient population.

      The primary study objective is to evaluate the effect of intraoperative infiltration of
      liposomal bupivacaine at the time of posterior colporrhaphy and/or perineorrhaphy on
      postsurgical pain scores during the first 72 hours after surgery as measured by visual analog
      scales (VAS).

      Secondary objectives include to evaluate total opioid consumption during the first 72
      postoperative hours, to evaluate patient satisfaction with postoperative analgesia, to
      evaluate time to first opioid administration postoperatively, to evaluate hospital length of
      stay, to evaluate length of stay in post-anesthesia care unit (PACU), to evaluate total
      hospital costs, to evaluate time to first bowel movement postoperatively, to evaluate rate of
      postoperative nausea and vomiting, to evaluate time to successful voiding trial, and to
      evaluate proportion of patients discharged home with a Foley catheter.

      Patients will be approached for participation preoperatively and randomized in the operating
      room to either liposomal bupivacaine or injectable normal saline administered into the
      posterior vaginal compartment in a standardized technique. All concurrent minimally invasive
      pelvic reconstructive surgical procedures are allowed. Randomization will be stratified for
      abdominal versus purely vaginal surgery. Perioperative care is standardized. Data will be
      abstracted from the medical record. Additionally, subjects will be discharged home with a
      medication diary and pain scales. Subjects will record their pain every morning and every
      evening for the first 72 hours after surgery. Subjects will complete a satisfaction survey at
      their 2 week postoperative visit. Adverse postoperative outcomes will be collected for 30
      days after surgery.

      The study is powered to detect a 20 mm difference in a 100 mm visual analog scale for pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 12, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Night of surgery (POD#0), POD#1 morning, POD#1 evening, POD#2 morning, POD#2 evening, POD#3 morning, POD#3 evening</time_frame>
    <description>As measured by a 100 mm Visual Analog Scale (VAS). This scale ranges from 0-100 mm with 0 mm indicating no pain and 100 mm indicating the most pain. The study is powered to detect a decrease in postoperative pain by 20 mm on this scale, which is considered to be a clinically meaningful difference in prior studies. Results will be reported as mean pain scores at each time point (night of surgery, morning and evening for the first 72 hours after surgery, i.e. until postoperative day#3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Satisfaction With Pain Control</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>As measured by a 5-question satisfaction survey administered at a 2 week postoperative visit. The survey includes Likert scale responses ranging from very unsatisfied to very satisfied with the surgical experience and specifically analgesia. &quot;Patient Satisfaction&quot; was defined as response &quot;satisfied&quot; or &quot;very satisfied&quot; on the Likert Scale. Average responses will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Administration</measure>
    <time_frame>Assessed up to 72 hours after surgery</time_frame>
    <description>Median time until first opioid administered after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Administration</measure>
    <time_frame>Cumulatively, over a time period of 72 hours after surgery</time_frame>
    <description>Measured in milligram morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Antiemetic Doses Required Per Participant While Inpatient</measure>
    <time_frame>Cumulatively, over a time period of 72 hours after surgery</time_frame>
    <description>Number of as-needed antiemetic doses patient received while in the hospital after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Assessed until 30 days after surgery</time_frame>
    <description>Total length of hospital stay measured in hours, including readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in Post-anesthesia Care Unit (PACU)</measure>
    <time_frame>Assessed up to 72 hours after surgery</time_frame>
    <description>Total length of stay in PACU measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had a Bowel Movement Within the First 3 Postoperative Days</measure>
    <time_frame>72 hours after surgery</time_frame>
    <description>As recorded by patient - patients were asked each postoperative day (i.e. POD#0, POD#1, POD#2, POD#3) if they had a bowel movement that day, yes or no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding Trial Failures</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>Proportion of patients discharged home with Foley catheters after failed voiding trials in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Assessed until 30 days after surgery</time_frame>
    <description>Total adverse postoperative events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Extended-release local anesthetic</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>EXPAREL 266 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - injection</intervention_name>
    <description>Injectable normal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English-speaking women ages 18 and older undergoing posterior repair and/or
             perineorrhaphy at our institution for pelvic organ prolapse

        Exclusion Criteria:

          -  Planned regional anesthesia

          -  Allergy or contraindication to bupivacaine

          -  Allergy or contraindication to opioids

          -  Allergy or contraindication to non-steroidal medications

          -  Planned laparotomy

          -  Chronic pain diagnosis and/or chronic narcotic use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study involves women undergoing surgery for pelvic organ prolapse</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Center for Pelvic Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Center for Pelvic Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <results_first_submitted>April 17, 2020</results_first_submitted>
  <results_first_submitted_qc>April 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2020</results_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Sarah Evans, MD</investigator_full_name>
    <investigator_title>Fellow Physician</investigator_title>
  </responsible_party>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>posterior repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03875664/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Excluded after enrollment if intraoperative decision made not to perform posterior colporrhaphy or perineorrhaphy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37">vaginal surgery n=18; vaginal + abdominal surgery n=19</participants>
                <participants group_id="P2" count="35">Vaginal surgery n=18; vaginal + abdominal surgery n=17</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="13.5"/>
                    <measurement group_id="B2" value="61" spread="26.7"/>
                    <measurement group_id="B3" value="62.7" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain</title>
        <description>As measured by a 100 mm Visual Analog Scale (VAS). This scale ranges from 0-100 mm with 0 mm indicating no pain and 100 mm indicating the most pain. The study is powered to detect a decrease in postoperative pain by 20 mm on this scale, which is considered to be a clinically meaningful difference in prior studies. Results will be reported as mean pain scores at each time point (night of surgery, morning and evening for the first 72 hours after surgery, i.e. until postoperative day#3).</description>
        <time_frame>Night of surgery (POD#0), POD#1 morning, POD#1 evening, POD#2 morning, POD#2 evening, POD#3 morning, POD#3 evening</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain</title>
          <description>As measured by a 100 mm Visual Analog Scale (VAS). This scale ranges from 0-100 mm with 0 mm indicating no pain and 100 mm indicating the most pain. The study is powered to detect a decrease in postoperative pain by 20 mm on this scale, which is considered to be a clinically meaningful difference in prior studies. Results will be reported as mean pain scores at each time point (night of surgery, morning and evening for the first 72 hours after surgery, i.e. until postoperative day#3).</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POD#0 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#1 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#1 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#2 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#2 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#3 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD#3 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Satisfaction With Pain Control</title>
        <description>As measured by a 5-question satisfaction survey administered at a 2 week postoperative visit. The survey includes Likert scale responses ranging from very unsatisfied to very satisfied with the surgical experience and specifically analgesia. &quot;Patient Satisfaction&quot; was defined as response &quot;satisfied&quot; or &quot;very satisfied&quot; on the Likert Scale. Average responses will be reported.</description>
        <time_frame>2 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Satisfaction With Pain Control</title>
          <description>As measured by a 5-question satisfaction survey administered at a 2 week postoperative visit. The survey includes Likert scale responses ranging from very unsatisfied to very satisfied with the surgical experience and specifically analgesia. &quot;Patient Satisfaction&quot; was defined as response &quot;satisfied&quot; or &quot;very satisfied&quot; on the Likert Scale. Average responses will be reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Administration</title>
        <description>Median time until first opioid administered after surgery</description>
        <time_frame>Assessed up to 72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Administration</title>
          <description>Median time until first opioid administered after surgery</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="60" upper_limit="219"/>
                    <measurement group_id="O2" value="68" lower_limit="60" upper_limit="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Administration</title>
        <description>Measured in milligram morphine equivalents</description>
        <time_frame>Cumulatively, over a time period of 72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Administration</title>
          <description>Measured in milligram morphine equivalents</description>
          <units>mme</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="40"/>
                    <measurement group_id="O2" value="37.5" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Antiemetic Doses Required Per Participant While Inpatient</title>
        <description>Number of as-needed antiemetic doses patient received while in the hospital after surgery</description>
        <time_frame>Cumulatively, over a time period of 72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Antiemetic Doses Required Per Participant While Inpatient</title>
          <description>Number of as-needed antiemetic doses patient received while in the hospital after surgery</description>
          <units>doses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Total length of hospital stay measured in hours, including readmissions</description>
        <time_frame>Assessed until 30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Total length of hospital stay measured in hours, including readmissions</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="20"/>
                    <measurement group_id="O2" value="24" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in Post-anesthesia Care Unit (PACU)</title>
        <description>Total length of stay in PACU measured in minutes</description>
        <time_frame>Assessed up to 72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in Post-anesthesia Care Unit (PACU)</title>
          <description>Total length of stay in PACU measured in minutes</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="61"/>
                    <measurement group_id="O2" value="93" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had a Bowel Movement Within the First 3 Postoperative Days</title>
        <description>As recorded by patient - patients were asked each postoperative day (i.e. POD#0, POD#1, POD#2, POD#3) if they had a bowel movement that day, yes or no.</description>
        <time_frame>72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Bowel Movement Within the First 3 Postoperative Days</title>
          <description>As recorded by patient - patients were asked each postoperative day (i.e. POD#0, POD#1, POD#2, POD#3) if they had a bowel movement that day, yes or no.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Voiding Trial Failures</title>
        <description>Proportion of patients discharged home with Foley catheters after failed voiding trials in the hospital</description>
        <time_frame>2 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Voiding Trial Failures</title>
          <description>Proportion of patients discharged home with Foley catheters after failed voiding trials in the hospital</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Total adverse postoperative events</description>
        <time_frame>Assessed until 30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Total adverse postoperative events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>We also investigated postoperative complications defined by the American College of Surgeons National Surgical Quality Improvement Program (NSQIP).
Adverse events were collected by chart review within 30 days of surgery. Charts were independently reviewed by 2 study personal for accuracy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
Liposomal bupivacaine: Extended-release local anesthetic</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
Placebo - injection: Injectable normal saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infections</sub_title>
                <description>9 urinary tract infections in placebo group; 4 urinary tract infections in liposomal bupivacaine group</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hospital readmission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Return to operating room</sub_title>
                <description>For midurethral sling revision</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sarah Evans</name_or_title>
      <organization>Atrium Health</organization>
      <phone>704-304-1660</phone>
      <email>sarah.evans@atriumhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

